NCT00541749

A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Escalating Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase I, randomized, placebo-controlled, double-blind, dose-escalation study of single and repeat doses of rhuMAb IFNalpha, administered through the SC or IV route, in adults with Systemic Lupus Erythematosus.

Conditions

• Systemic Lupus Erythematosus

Interventions

Type	Name	Description
DRUG	rhuMAb IFNalpha	Intravenous repeating dose

Timeline

• Start date: 2007-02-01
• First posted: 2007-10-10
• Last updated: 2011-09-22